StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — 360 One Capital

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

by360 One CapitalHorizon: NA (inferred 1 year)29 Sept 2026via NDTV Profit

Entry₹1,853.9Inferred
Target₹2,250
Total upside +21.37%
Stop lossNot given
CMP₹1,851.2Just now
Active-0.15%+21.54%upside left 12 mo left
Follow 360 One Capital for new callsGet alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 14 other Long-term calls on SUNPHARMASee 85 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Sept, 9:18 am IST
12 supporting3 neutral4 opposing
Supports the BUY call (12)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·29 Sept · yesterday

12 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·29 Sept · yesterday

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · 2d ago

(opens in new tab)

5 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · 6d ago

Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

NewsGoogle News·20 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (3)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (4)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.